Cybin inks a drug development agreement with Catalent, "the leading global provider" of drug delivery, development and manufacturing solutions.
Psychedelics
COMPASS Pathways granted two US patents
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
Investing in Psychedelics with MindMed Stock
It was the late Robin Williams who once said, “Reality is just a crutch for people who can’t handle drugs.”
MindMed Announces Inclusion in FTSE Russell Indexes
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Psychedelic Drugs: The Miracle Drugs of the 21st Century
Are psychedelics "miracle drugs"? If we compare them to the first Miracle Drug, the answer seems to be "yes".
Andrew Yang Urges Legalization Of Psilocybin And Marijuana At New York City Mayoral Forum
Andrew Yang, a former 2020 Democratic presidential candidate who is now running for mayor of New York City, said in a recent campaign forum that he supports legalizing psilocybin and marijuana.
Top Psychedelic Penny Stocks To Watch After Latest Big Pharma Deal
Psychedelic Penny Stocks Continue Gaining Ground Among Mainstream Investors
Numinus Announces Closing of $40-Million Bought Deal Financing
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.
How Analysts Are Asleep At The Wheel Regarding Psychedelic Stocks
Psychedelic drug stocks represent (by far) the best new opportunity in life sciences today. Institutional capital is flooding into the sector. But market analysts are asleep-at-the-wheel here.
Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader in Distribution of Psychedelics
Red Light Holland acquires a Netherlands distributor of psilocybin-based products.
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
MINDCURE adds a new tech specialist to direct the development of its iSTRYM R&D platform.
New research provides evidence that a single dose of psilocybin can boost brain connections
Scientists in Denmark believe the psychedelic substance psilocybin might produce rapid and lasting antidepressant effects in part because it enhances neuroplasticity in the brain.
Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing
Field Trip closes on a CAD$95 million bought deal financing, nearly double the original CAD$50 million offering.
Psychedelic Drug Development Or Clinics: Which Is The Better Path To Investor Profits?
Drug development or mental health clinics? We explore the benefits of both business strategies for investors in psychedelic stocks.
Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study
Cybin announces two new drug candidates for its R&D pipeline as its pre-clinical research deepens.